Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder

Sponsor
China Medical University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04118647
Collaborator
(none)
55
1
1
23
2.4

Study Details

Study Description

Brief Summary

Gastroesophageal reflux disorder (GERD) is due to gastric content reflux to esophagus cause symptom and complication including intra-esophagus such as reflux esophagitis, and extra-esophagus such as cough etc. Because the changes of dietary habit, and improvement of examination skill and data analysis, the prevalence of GERD increased 2.5 multiple from 1995 to 2002, and suggesting the prevalence is 25% in Taiwan community.

The etiology of GERD is multi-effect, such as transient lower esophageal sphincter relaxation and abnormal pressure of lower esophageal sphincter, which may induced the esophageal mucosal injury by gastric acid, bile or pancreases enzyme.

Wu-Chu-Yu tang consists of Evodia fargesii Dode (Evodia Fruit), Panax ginseng C. (Ginseng), Ziziphus jujube Mill (Chinses Date), Zingiber officinale Rosee (Fresh Ginger).According to "I-Fang-Chi-Chieh" and "Shanghonzobinglun" recordings that Wu-Chu-Yu tang can treat vomiting, and also can relax gastric tonicity and can enhance peristalsis of stomach. According to Randomized, double blind, placebo control trial to evaluate the efficacy of Wu-Chu-Yu Tang on gastroesophageal reflux disease, we know the Wu-Chu-Yu tang have the equivalent effect proton pump inhibitor omeprazole. But, the mechanism of Wu-Chu-Yu tang is still unknown.

Condition or Disease Intervention/Treatment Phase
  • Drug: Wu-Chu-Yu tang
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
55 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder
Anticipated Study Start Date :
Oct 1, 2019
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Sep 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Wu-Chu-Yu tang

Drug: Wu-Chu-Yu tang
Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.

Outcome Measures

Primary Outcome Measures

  1. 24 hours esophageal PH [28 days]

    Analysis the 24 hours PH change

  2. DeMeester score [28 days]

    DeMeester score had two major component as 1.total time of pH<4(%) and 2.number of reflux episode. Each major part had two minor component.Fist one, percentage of total time pH<4, had 1. percentage of upright time when pH<4 and 2.percentage of supine time when pH<4. Secondary part, number of reflux episode, had 1.number of reflux episode over 5 mintues and 2.longest reflux time. Finally, there was a composite score as the DeMeester score.

Secondary Outcome Measures

  1. Reflux Disease Questionnaire [56 days]

    Reflux Disease Questionnaire had one major component as Thinking about your symptoms over the past 7 days, how often have you had the following? And then there were six minor component: a. A burning feeling behind your breastbone b. Pain behind your breastbone c. A burning feeling in the centre of the upper stomach d. Pain in the centre of the upper stomach e. An acid taste in your mouth f. Unpleasant movement ofmaterial upwards from the stomach. Each question was different frequency as have not had, 1 day, 2 days, 3-4 days, 5-6 days or daily in one week. Each frequency had one score and subscale had score from one to six. The total score was one to thirty six. The score more less means more better outcome.

  2. SF-36 questionnaire [56 days]

    The scores of each question are added together to obtain the scale. The total score, the higher the total score, the quality of healthy life The higher.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Gender:male or female.

  2. Age:from 20 years old (inclusive) to 75 years old (inclusive).

  3. Diagnosis of gastroesophageal reflux disease.

  4. there is a heartburn or acid regurgitation phenomenon.

  5. After detailed description of the entire research purpose or process, voluntarily participate in the study and sign the consent form.

Exclusion Criteria:
  1. Exclude peptic ulcers, gallstones (including intrahepatic and common bile ducts) and major diseases such as: cancer, congestive hear failured NYHA class>II, COPD attack.

  2. Barrett's esophagus, narrow esophagus or caustic injury of upper gastrointestinal tract.

  3. History of esophagus and gastroduodenal surgery.

  4. Tarry stool suspected gastrointestinal bleeding.

  5. History of alcohol or drug abuse.

  6. Patients with a history of allergies to the test drug.

  7. Can not cooperate with mental illness.

  8. Pregnant women or women who are breastfeeding.

  9. Liver function SGOT and SGPT are more than twice the normal value.

  10. renal function test BUN, Creatinine is greater than the normal value.

Contacts and Locations

Locations

Site City State Country Postal Code
1 China Medical University Hospital Taichung North District Taiwan 40447

Sponsors and Collaborators

  • China Medical University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT04118647
Other Study ID Numbers:
  • CMUH108-REC2-101
First Posted:
Oct 8, 2019
Last Update Posted:
Oct 8, 2019
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 8, 2019